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osting by EAbstract Autoantibodies against C1q are strongly linked to immune-complex disorders like sys-
temic lupus erythematosus (SLE). Although anti-C1q antibodies have received much interest in
the recent years, their biological functions remain unclear. Anti-C1q antibodies are strongly asso-
ciated with lupus nephritis. The aim of this study was to determine the prevalence of anti-C1q anti-
bodies in Egyptian lupus patients as well as to evaluate the associations between anti C1q antibodies
and clinical and serologic parameters of patients with cutaneous and systemic lupus erythematosus.
Fifty-eight patients of lupus erythematosus were recruited in the study, and they were divided
into 3 groups according to their clinical presentations and laboratory investigations; group (1) con-
sists of 20 patients with musculoskeletal manifestations, mainly arthritis (34.5%), group (2) consists
of 12 patients with lupus nephritis (20%), and group (3) consists of 26 patients with cutaneous lupus
(44.8%). Fourteen age and sex matched healthy subjects served as controls. Complete blood pic-
ture, kidney function tests, liver function tests and anti-double stranded DNA were done for all
the studied patients. Anti-C1q antibodies were determined by immunometric enzyme immunoassay
for all the studied subjects.
Anti-C1q antibodies were positive in (63.8%) of lupus erythematosus (LE) patients and (0%) of
controls. Moreover, the serum anti-C1q antibodies titers were signiﬁcantly higher (P< 0.001) in all
lupus erythematosus patients (both systemic and cutaneous) when compared to healthy controls.
Surprisingly, serum anti-C1q antibodies were signiﬁcantly higher in patients with cutaneous lupus5720527.
(A.F. Barakat).
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168 A. Hegazy et al.than those with lupus nephritis (P< 0.001). Anti-C1q titers were signiﬁcantly correlated with levels
of anti–double stranded DNA (P< 0.001), as well as with proteinuria (<0.05) in lupus nephritis
patients.
It was concluded that anti C1q antibodies might play a pathogenic role in the pathogenesis of
cutaneous lupus and could positively be associated with evolution to SLE. Moreover, it could pre-
dict patients who subsequently develop nephritis, thus early use of immune modulators in cutane-
ous lupus could improve patients’ prognosis by decreasing the possibility of evolution to systemic
lupus complications, mainly nephritis.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Systemic Lupus erythematosus (SLE) is an autoimmune dis-
ease characterized by a broad clinical spectrum from cutane-
ous lesions to severe systemic manifestation. SLE is
characterized by acute and chronic inﬂammatory lesions lo-
cated either in skin (cutaneous lupus erythematosus – CLE)
or in any tissue and organ such as kidney and central nervous
system [1].
The complement system is one of the major effector mech-
anisms of the innate immune system and it plays an important
role in immunity [2]. C1q is the ﬁrst component of the classical
pathway of complement activation, and its main function is to
clear immune complexes from tissues and self antigens gener-
ated during apoptosis [3,4]. A prolonged exposure of C1q epi-
topes to the immune system could eventually lead to an
autoimmune response against itself [4]. Autoantibodies against
C1q have been found in many different autoimmune diseases,
and in 3–5% of normal individuals. Initially, anti-C1q anti-
bodies were observed in 100% of patients with hypocomple-
mentemic urticarial vasculitis and in 30–48% of patients with
SLE [5,6]. Subsequently they were strongly linked to other im-
mune-complex disorders such as rheumatoid vasculitis and
rheumatoid arthritis [1]. Over a third of SLE patients have a
high level autoantibodies–antigen complex that contains some
complement proteins, especially C1q as the trigger protein in
the classical complement activation pathway. So, the SLE, as
an autoimmune disease, is certainly related to disorders caused
by the activation of a complement system that ﬁnally leads to
tissue damage [7]. The hereditary deﬁciency (complement
genes mutations) of this component; C1q; is a known risk fac-
tor for the development of SLE [3]. In such a case, some com-
ponents of the complement system might be inactivated. Anti-
C1q antibodies were ﬁrst identiﬁed as low-molecular weight
C1q precipitins in the sera of patients with systemic lupus
erythematosus over 30 years ago. Anti-C1q antibodies are
strongly associated with the development of proliferative lupus
nephritis, so much so that active renal inﬂammation in SLE
patients is very unlikely if these antibodies are not present
[8]. Although anti-C1q antibodies have received much interest
in the recent years, their biological functions remain unclear.
However, their high negative predictive value for active lupus
nephritis suggests a pathogenic role in SLE patients. In addi-
tion, clearance of anti C1q antibodies by repeated plasmaphe-
resis or C1q immunoabsorption improved the clinical status of
SLE patients [9,10].
Speciﬁc events that occur during the development of sys-
temic lupus erythematosus (SLE) can be quite variable among
individual patients. In 88% of SLE patients, autoantibodies
are present in an average of 3.3 years before diagnosis [11].Identifying patterns that distinguish early clinical events in
SLE and the presence of associated autoantibodies which pre-
cedes the fulﬁllment of clinical criteria of SLE could help in
predicting the evolution of these patients to SLE [1].
Renal involvement is a serious clinical feature of systemic
lupus erythematosus and can present at any stage of the dis-
ease. Although its treatment and outcome have improved, lu-
pus nephritis is still a major contributor to morbidity [12], an
increase in anti-C1q antibody titer has been suggested to be
one of these autoantibodies which is able to predict renal ﬂares
in lupus nephritis so that monitoring anti-C1q might be valu-
able for the clinical management of SLE patients as a noninva-
sive biological marker. Therefore, it can inﬂuence therapeutic
decisions and reduce the number of invasive procedures such
as renal biopsies in patients with SLE [13].
Notably, there is increasing evidence that early diagnosis
and treatment could increase SLE remission rate and improve
patient prognosis. Although it has been shown that autoanti-
bodies appear before clinical manifestations in SLE patients,
currently we cannot predict which autoantibody positive sub-
jects will eventually develop the disease. Thus, great effort
should be taken in order to identify new biomarkers able to
improve our diagnostic potential, from these, anti-C1q anti-
bodies are among the most promising [14]. Although anti-
C1q antibodies are expressed mainly in SLE patients with lu-
pus nephritis [15–17], some cutaneous lupus patients expressed
anti-C1q antibodies [18].
The aim of this study was to determine the prevalence of
anti-C1q antibodies in Egyptian lupus erythematosus patients
as well as to evaluate the associations between anti-C1q anti-
bodies and clinical and serologic parameters of patients with
cutaneous and systemic lupus erythematosus.
2. Subjects and methods
Fifty-eight lupus erythematosus patients (M/F: 3/55; mean
age ± SD: 41 ± 10.3 years) were recruited in the study from
those attending Rheumatology and Immunology Unit of
Internal Medicine Department and Dermatology Department
of Mansoura University Hospital from the period of March,
2010 to June, 2011. Patients were divided into 3 groups accord-
ing to their clinical presentations and laboratory investiga-
tions; group (1) comprised of 20 SLE patients with
musculoskeletal manifestations, mainly arthritis (34.5%),
group (2) comprised of 12 patients with lupus nephritis
(20%), both groups fulﬁlling at least 4 of 11 American College
of Rheumatology (ACR) criteria for classiﬁcation of SLE [19]
but had neither skin lesions nor photosensitivity, and group (3)
consists of 26 patients with cutaneous lupus (photosensitivity,
malar rash and/or discoid lupus) (44.8%) who did not fulﬁll a
Table 2 Comparison between prevalence and serum titers of
anti-C1q antibody in systemic lupus erythematosus patients
versus control.
Anti-C1q antibodies Systemic lupus
erythematosus
(n= 58) (%)
Controls
(n= 14)
(%)
P
Prevalence 37/58 (63.8%) 0/14 (0%) <0.0001
Serum titers
Median (range):U/ml 17.6 (1.5–341) 2.5 (0.9–4.2) <0.0001
Table 3 Association between the anti-C1q antibodies level
and the laboratory parameters of systemic lupus erythematosus
patients.
Laboratory parameter Anti-C1q antibodies
r P value
Serum creatinine 0.152 NS
Proteinuria 0.504 <0.001
Serum albumin 0.022 NS
Erythrocyte sedimentation rate 0.951 NS
Hemoglobin 0.191 NS
Leucocytes 0.271 NS
Platelets 0.254 NS
Anti-ds DNA titer 0.459 <0.001
Table 4 Relation between anti-C1q and anti-double stranded
DNA in lupus erythematosus patients.
Anti-ds DNA Systemic lupus
erythematosus
number/total (%)
Anti-C1q antibodies
median (range)
P
Positive 36/58 (62.1%) 34.0 (2.7–341)
Negative 22/58 (37.9%) 6.7 (1.5–38) <0.0001
Table 5 Relation between anti-C1q antibodies and clinical
parameters in LE patients.
Parameters Anti C1q (U/ml) P
Median Range
Arthritis (20/58) 4.65 1.5–22
Nephritis (12/58) 31.05 11–46.8 <0.0001
Skin (26/58) 36.0 12.5–341
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and had neither proteinuria nor elevated serum creatinine. In
addition 14 age and sex matched healthy subjects served as
the control group. Subjects with positive hepatitis C antibod-
ies, serum hepatitis B surface antigen expression and signs of
acute microbial inﬂammation were excluded.
Complete history, physical examination and complete
blood picture, kidney function tests, liver function tests, eryth-
rocyte sedimentation rate (ESR) and urine analysis were done
for all the studied patients. Renal biopsies were performed to
conﬁrm lupus nephritis by histopathology in most of the lupus
nephritis patients.
All participants underwent an immunological study includ-
ing anti-double stranded (anti-ds) DNA (IU/ml) and anti-C1q
antibodies serum level. Anti-c1q was assayed by immunomet-
ric enzyme immunoassay supplied by Orgentec Diagnostika
GmbH (Germany) [20]. Results were expressed as unit/ml
(U/ml) and positive anti-C1q was considered if the serum level
was more than 10 U/ml, as recommended by the manufacturer
as the cutoff value. Informed consent was obtained from all
participants.
2.1. Statistical analysis
The statistical analysis of data was done using SPSS (SPSS,
Inc. Chicago, IL), program statistical package for Social Sci-
ence (version 16). To test the normality of data distribution
K-S (Kolmogorov–Smirnov) test was done and only signiﬁ-
cant data were revealed to be nonparametric. The description
of the data was done in form of mean ± standard deviation
(mean ± SD for quantitative data. Nonparametric data were
expresses as median and range. For quantitative data student
t-test was used to compare between two groups. Mann–
Whitney test and Kruskal Wallis were used for non parametric
data. To test the association between variables Pearson corre-
lation co-efﬁcient test was used. P is considered signiﬁcant if
60.05 at conﬁdence interval 95% [21].
3. Results
The clinical parameters of the studied lupus erythematosus
groups are described in Table 1.
The prevalence and titers of anti-C1q Antibodies were sig-
niﬁcantly (P< 0.0001) higher in systemic lupus erythematosus
(SLE) patients than in controls (Table 2).
Anti-C1q antibodies were signiﬁcantly correlated with pro-
teinuria in lupus nephritis patients, but not with serum creati-
nine, serum albumin, ESR, hemoglobin, leucocytes or platelets
(Table 3).Table 1 Clinical parameters of groups of lupus erythematosus
patients.
Group Number (n= 58) (%)
Group 1
Musculoskeletal manifestations (Arthritis) 20 34.48
Group 2
Lupus nephritis 12 20.68
Group 3
Cutaneous lupus 26 44.82Moreover, there was statistically signiﬁcant positive corre-
lation (P< 0.001) between titers of anti-C1q antibodies and
anti-double stranded-DNA titers (Table 3). Furthermore, the
prevalence of anti-C1q antibodies was signiﬁcantly higher in
lupus erythematosus patients who were positive for anti-dou-
ble stranded DNA (P< 0.0001) in comparison to negative
anti-ds DNA patients (Table 4).
Surprisingly, anti-C1q antibodies titers were signiﬁcantly
higher in patients with cutaneous lupus when compared to lu-
pus nephritis patients and systemic lupus erythematosus with
musculoskeletal manifestations, (the median values were
36.0, 31.05, and 4.65 U/ml respectively, P < 0.0001 for all).
Data are shown in Table 5 and Fig. 1.
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Figure 1 Anti-C1q antibodies in different groups of lupus
erythematosus.
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In the present study it was observed that there was signiﬁcant
relation between serum anti-C1q antibodies and proteinuria in
lupus nephritis patients, on the other hand there was no corre-
lation between anti-C1q antibodies and serum creatinine, ser-
um albumin, complete blood picture parameters as well as
ESR. These results were in accordance with previous studies
that conﬁrmed correlation between anti-C1q antibodies and
lupus nephritis [15–17,22] and in parallel with a recent report
by Fang et al. [23]. However, this previous study demonstrated
signiﬁcant correlations with creatinine and leucopenia [23].
This discrepancy in results may be ascribable to differences
in patients’ population and anti-C1q antibodies assays.
Moreover, a signiﬁcant positive relation was found between
anti-C1q antibodies and positivity as well as titers of anti-ds
DNA. These results were consistent with those from a study
by Mok et al., who demonstrated that the anti-C1q antibodies
were correlated to positive anti-ds DNA and also conﬁrmed
that anti-C1q antibodies were more speciﬁc than anti-ds
DNA for concurrent both active renal and extra renal lupus,
and that the absence of both anti-ds DNA and anti-C1q anti-
bodies had a high negative predictive value for renal activity
[24].
Interestingly, in the present study it was found that in cuta-
neous lupus patients, serum levels of anti-C1q antibodies were
statistically signiﬁcantly higher when compared to other lupus
groups as well as to controls, although some previous studies
detected no difference between serum anti-C1q antibody in
systemic lupus and cutaneous lupus manifestations
[12,13,25], in which the number of patients recruited with cuta-
neous manifestations was relatively small. A recent study by
Eugenia and colleagues stated that anti-C1q antibodies might
play a pathogenic role in subcutaneous lupus erythematosus
(SCLE) pathogenesis and being positively associated with
cutaneous apoptosis markers and might be associated with a
negative prognosis and secondary SLE development [18].
Thus, the present study suggests that anti-C1q antibodies be-
sides their good negative predictive value they have for lupus
nephritis in SLE patients, might have a positive predictivevalue for cutaneous lupus evolution to SLE, especially lupus
nephritis. This suggestion was supported also by a previous
study by Heilen et al. who found that the clinical features that
were observed earliest in lupus patients were discoid rash and
seizures, and that anti-double-stranded DNA antibodies were
associated with renal disease and appeared before evidence
of nephritis in most patients. This means that the development
of organ-associated autoantibodies generally precedes the
appearance of their associated clinical features [1].
In recent years, some therapeutic options have emerged as
appropriate interventions for early SLE treatment such as anti-
malarials, vitamin D, statins, and vaccination with self derived
peptides. All these immune modulators seem to be particularly
useful when introduced in an early stage of the disease [14]. We
suggest that these immune modulators could be used also early
in cutaneous lupus to decrease the possibility of evolution to
SLE.
In conclusion, our results conﬁrmed that anti-C1q antibod-
ies are present in a signiﬁcant percentage of cutaneous lupus
and in SLE patients with active renal involvement, suggesting
that these antibodies might play a pathogenic role in the path-
ogenesis of cutaneous lupus and that it could be a useful addi-
tional marker for early diagnosis. Moreover, it could be of
interest for monitoring and follow-up of cutaneous lupus ery-
thematosus (CLE) patients and in predicting those at risk of
subsequent renal involvement or ﬂare. Thus, besides the good
negative predictive value that these antibodies have for lupus
nephritis in SLE they may have a positive predictive value
for cutaneous LE evolution to SLE. So, determination of the
level of anti-C1q antibodies in serum specimens could have
not only a great diagnostic importance but also have a good
therapeutic challenge if used early in the disease. Further
large-scale multicentre prospective studies are needed to eluci-
date the clinical signiﬁcance of anti-C1q antibodies in the
prognosis of cutaneous lupus and to explore the possibility
of its role in evolution to systemic lupus erythematosus and
validate the importance of early immune modulators treatment
in cutaneous lupus to improve patients’ prognosis and decrease
subsequent development of systemic lupus erythematosus
complications, mainly lupus nephritis.
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